The principal findings of the current study indicated that patients in the pancreatic cancer (PC) group exhibited significantly elevated CEA levels compared to those with benign gastrointestinal tract (GIT) diseases and healthy controls. This evidence concerns the gene CEACAM5 and pancreatic neoplasm.